StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Stock analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th.

Cytosorbents Stock Up 1.1 %

Shares of NASDAQ CTSO opened at $0.93 on Tuesday. The firm has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.01. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $2.15. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $50.85 million, a PE ratio of -2.58 and a beta of 0.56.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Sargent Investment Group LLC boosted its stake in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after acquiring an additional 192,747 shares in the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents during the third quarter valued at approximately $51,000. Geode Capital Management LLC boosted its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, CM Management LLC grew its stake in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after buying an additional 25,000 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.